Senate okays expanded stem cell funding

In a largely symbolic victory for biomedical research, the Senate today (July 18) approved a linkurl:controversial bill;http://www.the-scientist.com/news/display/23895/ (HR 810) to extend Federal research funding to newly derived human embryonic stem cells (hESC). The legislation faces a veto from President Bush, who opposes the expansion of funding on ethical grounds. Indeed, on Monday (July 17) the White House reaffirmed the president?s intention to veto the bill. After 12 hours of discussi

Written byAlison McCook
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
In a largely symbolic victory for biomedical research, the Senate today (July 18) approved a linkurl:controversial bill;http://www.the-scientist.com/news/display/23895/ (HR 810) to extend Federal research funding to newly derived human embryonic stem cells (hESC). The legislation faces a veto from President Bush, who opposes the expansion of funding on ethical grounds. Indeed, on Monday (July 17) the White House reaffirmed the president?s intention to veto the bill. After 12 hours of discussion and debate that began Monday afternoon, the ?Stem Cell Research Enhancement Act of 2005? passed the Senate with wide bipartisan support by 63-37. While it passed by wide margins, there are likely not enough votes in either the House of Representatives or in the Senate to linkurl:over-ride a veto.;http://www.the-scientist.com/news/display/23595/ The House, which originated and already passed the bill, is expected to an attempt a veto over-ride this week or next. If that effort fails, the bill is dead and would need to be reintroduced next year. The Senate also approved two less-contentious bills that the president supports, which direct the National Institutes of Health to support research into ways to derive hESCs without destroying human embryos (which the NIH already does) and prohibit trafficking human fetal tissue ?gestated for research purposes.? This information was contributed by reporter Ted Agres, who has been following the story. Look for expanded coverage of this issue in tomorrow's edition of The Scientist.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies